Date of Award
Honors College Thesis
Fengwei Bai, Ph.D.
West Nile virus (WNV), a positive sense single stranded RNA flavivirus, is prevalent in many countries worldwide and is a growing threat in the United States. Some patients infected with WNV develop severe neuroinvasive disease including meningitis or encephalitis which may lead to death. The recently characterized cytokine interleukin-17 (IL-17) has been implicated in several autoimmune diseases, neuroinflammatory conditions, and immune responses to various microbial infections. Previous research has indicated that a known contributor to IL-17 production, interleukin-23, is produced in response to WNV infection, but the role of IL-17 during WNV infection has not been studied before. This study found that WNV infected IL-17 deficient (IL-17-/-) mice developed higher viral loads in the blood and brain compared to wild-type (WT) control mice and were susceptible to severe WNV infection (IL-17-/- 20% survival; WT 60% survival). Interestingly, CD8+ T cells isolated from IL-17-/- mice infected with WNV showed reduced cytotoxicity compared to WT CD8+ T cells. These results suggest that IL-17 plays a protective role during WNV infection by contributing to the cytotoxicity of CD8+ T cells. CD8+ T cells have previously been shown to play a protective role during WNV infection, but little is known about the activation CD8+ T cells or their recruitment to WNV infected cells. Further studies are warranted to elucidate the mechanism by which IL-17 signaling regulates CD8+T cell responses during WNV infection.
Copyright for this thesis is owned by the author. It may be freely accessed by all users. However, any reuse or reproduction not covered by the exceptions of the Fair Use or Educational Use clauses of U.S. Copyright Law or without permission of the copyright holder may be a violation of federal law. Contact the administrator if you have additional questions.
Lowery, Jordan E., "Role of IL-17 in CD8+ T cell mediated clearance of West Nile virus" (2014). Honors Theses. 329.